+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Argatroban Market by Product Type, Application, End-User, Therapeutic Area, Route Of Administration - Global Forecast 2025-2030- Product Image
Argatroban Market by Product Type, Application, End-User, Therapeutic Area, Route Of Administration - Global Forecast 2025-2030- Product Image
Sale

Argatroban Market by Product Type, Application, End-User, Therapeutic Area, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013907
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Argatroban Market grew from USD 64.68 million in 2023 to USD 67.34 million in 2024. It is expected to continue growing at a CAGR of 4.09%, reaching USD 85.67 million by 2030.

Argatroban is a synthetic direct thrombin inhibitor primarily used as an anticoagulant for patients with heparin-induced thrombocytopenia (HIT) and in percutaneous coronary intervention in patients at risk of HIT. Its necessity arises from its unique mechanism of action and effectiveness in scenarios where traditional anticoagulants like heparin are unsuitable or cause adverse effects. The application and end-use scope of Argatroban are largely tied to hospital settings, particularly intensive care units and specialist cardiac intervention teams, where rapid anticoagulation without the limitations of heparin is required. Key growth factors influencing Argatroban's market include the rising incidence of HIT, increased procedures requiring anticoagulation, and broader awareness among healthcare professionals of its benefits. Recent potential opportunities lie in expanding indications, regulatory approvals in new regions, and further research into optimizing dosing protocols for specific patient subgroups. Despite its advantages, the market faces challenges such as high costs compared to other anticoagulants, limited awareness in developing regions, and stringent regulatory requirements which can slow new approvals. Innovating in areas such as cost-effective supply chains, developing generic formulations, and conducting large-scale trials to explore broader applications could yield substantial growth. Additionally, research focused on personalized medicine approaches and therapeutic drug monitoring enhanced by digital health technologies may drive future market expansion. The nature of the Argatroban market is dynamic, highly specialized, and characterized by rigorous clinical validation standards. Companies aiming to leverage the Argatroban market should focus on collaborative research with academic institutions, investment in targeted marketing strategies to educate healthcare providers, and partnerships with healthcare organizations to integrate Argatroban into broader treatment protocols. Recognizing the delicate balance between cost, efficacy, and safety will be vital in navigating and thriving in this competitive market landscape.

Understanding Market Dynamics in the Argatroban Market

The Argatroban Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
    • Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
    • Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
    • Strategic partnerships and collaborations among key players driving argatroban market dynamics
  • Market Restraints
    • High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
    • Competition among other anticoagulants and emerging therapies
  • Market Opportunities
    • Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
    • Increasing investments in research and development for novel anticoagulant drugs
    • Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
  • Market Challenges
    • Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
    • Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products

Exploring Porter’s Five Forces for the Argatroban Market

Porter’s Five Forces framework further strengthens the insights of the Argatroban Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Argatroban Market

External macro-environmental factors deeply influence the performance of the Argatroban Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Argatroban Market

The Argatroban Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Argatroban Market

The Argatroban Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Argatroban Market

The Argatroban Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Argatroban Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Eagle Pharmaceuticals Inc., Fresenius Kabi AG, GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Pfizer Inc., Sandoz (a Novartis Division), Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Argatroban Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product Type
    • Dosage Strength
      • 1 mg/mL
      • 2 mg/mL
    • Formulations
      • Injectable Solutions
      • Powder For Solution
  • Application
    • Percutaneous Coronary Intervention
      • During Procedure
      • Post-Procedure Care
    • Treatment Of Heparin-Induced Thrombocytopenia
      • Acute Cases
      • Chronic Cases
  • End-User
    • Ambulatory Surgical Centers
      • Hospital-Associated Centers
      • Standalone Centers
    • Clinics
      • General Clinics
      • Specialized Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Therapeutic Area
    • Cardiology
      • Invasive Cardiology
      • Non-Invasive Cardiology
    • Critical Care
      • Emergency Care
      • Intensive Care
    • Hematology
      • Blood Disorders
      • Coagulopathies
  • Route Of Administration
    • Intracardiac Administration
    • Intravenous Administration
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Advancements in anticoagulant formulations and delivery systems improving argatroban efficacy and patient compliance
5.1.1.2. Increasing investment in healthcare infrastructure and anticoagulant research propelling argatroban market expansion
5.1.1.3. Growing awareness and diagnosis of thromboembolic disorders contributing to higher argatroban market penetration
5.1.1.4. Strategic partnerships and collaborations among key players driving argatroban market dynamics
5.1.2. Restraints
5.1.2.1. High initial cost of argatroban, limiting its accessibility in cost-sensitive markets
5.1.2.2. Competition among other anticoagulants and emerging therapies
5.1.3. Opportunities
5.1.3.1. Growing demand for anticoagulant therapies due to rise in cardiovascular diseases
5.1.3.2. Increasing investments in research and development for novel anticoagulant drugs
5.1.3.3. Expansion of the argatroban market in emerging economies with a focus on healthcare improvement
5.1.4. Challenges
5.1.4.1. Limited availability of raw materials and supply chain disruptions affecting argatroban production processes
5.1.4.2. Stringent regulatory approvals and compliance requirements hindering the innovation and market entry of argatroban products
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Argatroban Market, by Product Type
6.1. Introduction
6.2. Dosage Strength
6.2.1. 1 mg/mL
6.2.2. 2 mg/mL
6.3. Formulations
6.3.1. Injectable Solutions
6.3.2. Powder For Solution
7. Argatroban Market, by Application
7.1. Introduction
7.2. Percutaneous Coronary Intervention
7.2.1. During Procedure
7.2.2. Post-Procedure Care
7.3. Treatment Of Heparin-Induced Thrombocytopenia
7.3.1. Acute Cases
7.3.2. Chronic Cases
8. Argatroban Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.2.1. Hospital-Associated Centers
8.2.2. Standalone Centers
8.3. Clinics
8.3.1. General Clinics
8.3.2. Specialized Clinics
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals
9. Argatroban Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiology
9.2.1. Invasive Cardiology
9.2.2. Non-Invasive Cardiology
9.3. Critical Care
9.3.1. Emergency Care
9.3.2. Intensive Care
9.4. Hematology
9.4.1. Blood Disorders
9.4.2. Coagulopathies
10. Argatroban Market, by Route Of Administration
10.1. Introduction
10.2. Intracardiac Administration
10.3. Intravenous Administration
11. Americas Argatroban Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Argatroban Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Argatroban Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ARGATROBAN MARKET RESEARCH PROCESS
FIGURE 2. ARGATROBAN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ARGATROBAN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ARGATROBAN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ARGATROBAN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ARGATROBAN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ARGATROBAN MARKET DYNAMICS
TABLE 7. GLOBAL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ARGATROBAN MARKET SIZE, BY 1 MG/ML, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ARGATROBAN MARKET SIZE, BY 2 MG/ML, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ARGATROBAN MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ARGATROBAN MARKET SIZE, BY POWDER FOR SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ARGATROBAN MARKET SIZE, BY DURING PROCEDURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ARGATROBAN MARKET SIZE, BY POST-PROCEDURE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ARGATROBAN MARKET SIZE, BY ACUTE CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ARGATROBAN MARKET SIZE, BY CHRONIC CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITAL-ASSOCIATED CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ARGATROBAN MARKET SIZE, BY STANDALONE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ARGATROBAN MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ARGATROBAN MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ARGATROBAN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ARGATROBAN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ARGATROBAN MARKET SIZE, BY INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ARGATROBAN MARKET SIZE, BY NON-INVASIVE CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ARGATROBAN MARKET SIZE, BY EMERGENCY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ARGATROBAN MARKET SIZE, BY INTENSIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ARGATROBAN MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ARGATROBAN MARKET SIZE, BY COAGULOPATHIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ARGATROBAN MARKET SIZE, BY INTRACARDIAC ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ARGATROBAN MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. CANADA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. CANADA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 102. CANADA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 103. CANADA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. CANADA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 105. CANADA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 106. CANADA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. CANADA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 108. CANADA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. CANADA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. CANADA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 111. CANADA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 112. CANADA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 113. CANADA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 114. CANADA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 117. MEXICO ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 120. MEXICO ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 121. MEXICO ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. MEXICO ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. MEXICO ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 127. MEXICO ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES ARGATROBAN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. CHINA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. CHINA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 179. CHINA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 180. CHINA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. CHINA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 182. CHINA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 183. CHINA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. CHINA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 185. CHINA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 186. CHINA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. CHINA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. CHINA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 189. CHINA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 190. CHINA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 191. CHINA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. INDIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. INDIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 194. INDIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 195. INDIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. INDIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 197. INDIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 198. INDIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. INDIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 200. INDIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 201. INDIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 202. INDIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 203. INDIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 204. INDIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 205. INDIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 206. INDIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. JAPAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. JAPAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 224. JAPAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 225. JAPAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. JAPAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 227. JAPAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 228. JAPAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. JAPAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 230. JAPAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. JAPAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 232. JAPAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 233. JAPAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 234. JAPAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 235. JAPAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 236. JAPAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. SOUTH KOREA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 287. SOUTH KOREA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 288. SOUTH KOREA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. SOUTH KOREA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 290. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 291. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH KOREA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 293. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 294. SOUTH KOREA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 295. SOUTH KOREA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 296. SOUTH KOREA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. TAIWAN ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. TAIWAN ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 299. TAIWAN ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 300. TAIWAN ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. TAIWAN ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 302. TAIWAN ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 303. TAIWAN ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 304. TAIWAN ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 305. TAIWAN ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. TAIWAN ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. TAIWAN ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 308. TAIWAN ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 309. TAIWAN ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 310. TAIWAN ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 311. TAIWAN ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. THAILAND ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. THAILAND ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 314. THAILAND ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 315. THAILAND ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. THAILAND ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 317. THAILAND ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 318. THAILAND ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. THAILAND ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 320. THAILAND ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 321. THAILAND ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 322. THAILAND ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 323. THAILAND ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 324. THAILAND ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 325. THAILAND ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 326. THAILAND ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 327. VIETNAM ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. VIETNAM ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 329. VIETNAM ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 330. VIETNAM ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. VIETNAM ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 332. VIETNAM ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 333. VIETNAM ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 334. VIETNAM ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 335. VIETNAM ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 336. VIETNAM ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. VIETNAM ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 338. VIETNAM ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 339. VIETNAM ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 340. VIETNAM ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 341. VIETNAM ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 343. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 344. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 345. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2030 (USD MILLION)
TABLE 347. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA, 2018-2030 (USD MILLION)
TABLE 348. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 349. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 350. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 351. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 352. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 353. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 354. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY CRITICAL CARE, 2018-2030 (USD MILLION)
TABLE 355. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 356. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 357. EUROPE, MIDDLE EAST & AFRICA ARGATROBAN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 358. DENMARK ARGATROBAN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 359. DENMARK ARGATROBAN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 360. DENMARK ARGATROBAN MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 361. DENMARK ARGATROBAN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 362. DENMARK ARGATROBAN MARKET SIZE, BY PERCUTANEOUS CORONA

Companies Mentioned

The leading players in the Argatroban market, which are profiled in this report, include:
  • Abbvie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eagle Pharmaceuticals Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz (a Novartis Division)
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 67.34 Million
Forecasted Market Value ( USD ) by 2030 $ 85.67 Million
Compound Annual Growth Rate4.0%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Chemotherapy Induced Anemia Market by Range Of Anemia, Treatment, Drug, End-User - Global Forecast 2025-2030 - Product Image

Chemotherapy Induced Anemia Market by Range Of Anemia, Treatment, Drug, End-User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Antiplatelet Market by Drug Type (Abciximab, Aspirin, Clopidogrel), Drug Formulation (Capsule, Injection, Tablet), Indication, Mechanism of Action, Mode of Administration, Distribution Channel, End-user - Global Forecast 2025-2030 - Product Image

Antiplatelet Market by Drug Type (Abciximab, Aspirin, Clopidogrel), Drug Formulation (Capsule, Injection, Tablet), Indication, Mechanism of Action, Mode of Administration, Distribution Channel, End-user - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class (Corticosteroids, Immunosuppressive Agents), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class (Corticosteroids, Immunosuppressive Agents), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From

About the Argatroban Market

Argatroban is a hematological drug used to treat and prevent blood clots in patients with certain conditions. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the clotting process. It is used to treat and prevent thrombosis in patients with heparin-induced thrombocytopenia (HIT), a condition in which the body produces antibodies against heparin, a commonly used anticoagulant. It is also used to treat and prevent thrombosis in patients with other conditions, such as atrial fibrillation and deep vein thrombosis. Argatroban is available in both intravenous and subcutaneous formulations. It is typically administered as an intravenous infusion over a period of several hours, or as a subcutaneous injection. The drug is available in a variety of strengths and formulations, and is typically prescribed by a doctor. The Argatroban market is highly competitive, with several companies offering the drug. Some of the major players in the market include Pfizer, Sanofi, Bristol-Myers Squibb, and Bayer. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.